Beclabuvir for the treatment of hepatitis C
| Autor: | Antonio Riccardo Buonomo, Guglielmo Borgia, Ivan Gentile, Emanuela Zappulo, Alberto Enrico Maraolo |
|---|---|
| Přispěvatelé: | Gentile, Ivan, Zappulo, Emanuela, Buonomo, ANTONIO RICCARDO, Maraolo, ALBERTO ENRICO, Borgia, Guglielmo |
| Rok vydání: | 2015 |
| Předmět: |
hepatitis C virus
Indoles Daclatasvir Cirrhosis Genotype Hepatitis C virus Hepacivirus Biology medicine.disease_cause Antiviral Agents allosteric NS5B polymerase inhibitor chemistry.chemical_compound IFN-free combination eradication Drug Resistance Viral medicine Animals Humans Pharmacology (medical) BMS-791325 Beclabuvir direct-acting antiviral agent Pharmacology General Medicine Hepatitis C Benzazepines Hepatitis C Chronic medicine.disease antiviral Virology Tolerability chemistry Hepatocellular carcinoma Asunaprevir Drug Therapy Combination medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 24:1111-1121 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1517/13543784.2015.1059820 |
| Popis: | About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however, several new direct-acting antivirals against HCV are available or are in an advanced phase of clinical development.This review focuses on beclabuvir , an allosteric non-nucleotide inhibitor of HCV polymerase. The article covers its pharmacokinetics, mechanism of action, in addition to its tolerability and safety profile as well as its resistance pattern.The pharmacokinetic, efficacy and tolerability profile of beclabuvir, as well as its barrier to resistance, are very favorable. In particular, the combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide. Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|